Literature DB >> 28690138

Chinese herbal medicine for Alzheimer's disease: Clinical evidence and possible mechanism of neurogenesis.

Wen-Ting Yang1, Xia-Wei Zheng1, Shuang Chen1, Chun-Shuo Shan1, Qing-Qing Xu1, Jia-Zhen Zhu2, Xiao-Yi Bao2, Yan Lin1, Guo-Qing Zheng3, Yan Wang4.   

Abstract

Currently, there is lack of cure or disease-modifying treatment for Alzheimer's disease (AD). Chinese herbal medicine (CHM) is purported to ameliorate AD progression, perhaps by promoting hippocampal neurogenesis. Here, we conducted an updated systematic review to investigate the efficacy and safety of CHM for AD based on high-quality randomized controlled trials (RCTs) and reviewed its possible mechanisms of neurogenesis according to animal-based researches. Twenty eligible studies with 1767 subjects were identified in eight database searches from inception to February 2017. The studies investigated the CHM versus placebo (n=3), CHM versus donepezil (n=9 with 10 comparisons), CHM plus donepezil versus donepezil (n=3), CHM versus a basic treatment (n=3), and CHM plus basic treatment versus basic treatment (n=2). Adverse events were reported in 11 studies, analyzed but not observed in 3 studies, and not analyzed in 6 studies. The main findings of present study are that CHM as adjuvant therapy exerted an additive anti-AD benefit, whereas the efficacy of CHM as a monotherapy was inconclusive. Additionally, CHMs were generally safe and well tolerated in AD patients. Active molecules in frequent constituents of CHMs can alter multiple critical signaling pathways regulating neurogenesis. Thus, the present evidence supports, to a limited extent, the conclusion that CHM can be recommended for routine use in AD patients and its possible mechanism enhances adult hippocampal neurogenesis through activating the multi-signal pathways.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Astragaloside IV (PubChem CID: 13943297); Catalpol (PubChem CID: 91520); Dementia; Ginsenoside Rb1 (PubChem CID: 9898279); Ginsenoside Rg1 (PubChem CID: 441923); Glabridin (PubChem CID: 124052); Icariin (PubChem CID: 5318997); Liquiritin (PubChem CID: 503737); Mini-Mental State Examination; Neurogenesis; Salvianolic acid A (PubChem CID: 5281793); Systematic review; Tanshinone I (PubChem CID: 114917); Tetramethylpyrazine (PubChem CID: 14296); Traditional Chinese medicine

Mesh:

Substances:

Year:  2017        PMID: 28690138     DOI: 10.1016/j.bcp.2017.07.002

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  29 in total

Review 1.  Current Progress on Neuroprotection Induced by Artemisia, Ginseng, Astragalus, and Ginkgo Traditional Chinese Medicines for the Therapy of Alzheimer's Disease.

Authors:  Qin Li; Limor Rubin; Marta Silva; Shuai Li; Chao Yang; Philip Lazarovici; Wenhua Zheng
Journal:  Oxid Med Cell Longev       Date:  2022-06-14       Impact factor: 7.310

2.  Efficacy of Jihwangeumja (Dihuang Yinzi) on cognitive function and activities of daily living in patients with Alzheimer disease: A protocol for a systematic review and meta-analysis.

Authors:  Jae Yeong Lee; Ju Yeon Kim; Ji-Yoon Lee; Jin-Hyeong Jung; In Chul Jung
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

Review 3.  Alzheimer's disease hypothesis and related therapies.

Authors:  Xiaoguang Du; Xinyi Wang; Meiyu Geng
Journal:  Transl Neurodegener       Date:  2018-01-30       Impact factor: 8.014

4.  Adding Chinese herbal medicine to conventional therapy brings cognitive benefits to patients with Alzheimer's disease: a retrospective analysis.

Authors:  Jing Shi; Jingnian Ni; Tao Lu; Xuekai Zhang; Mingqing Wei; Ting Li; Weiwei Liu; Yongyan Wang; Yuanyuan Shi; Jinzhou Tian
Journal:  BMC Complement Altern Med       Date:  2017-12-13       Impact factor: 3.659

5.  Herbal Medicine Formulas for Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Double-Blind Placebo-Controlled Clinical Trials.

Authors:  Chun-Shuo Shan; Hong-Feng Zhang; Qing-Qing Xu; Yi-Hua Shi; Yong Wang; Yan Li; Yan Lin; Guo-Qing Zheng
Journal:  Front Aging Neurosci       Date:  2018-11-08       Impact factor: 5.750

6.  Rhynchophylline Loaded-mPEG-PLGA Nanoparticles Coated with Tween-80 for Preliminary Study in Alzheimer's Disease.

Authors:  Ruiling Xu; Junying Wang; Juanjuan Xu; Xiangrong Song; Hai Huang; Yue Feng; Chunmei Fu
Journal:  Int J Nanomedicine       Date:  2020-02-18

7.  Identification of Multi-Target Anti-AD Chemical Constituents From Traditional Chinese Medicine Formulae by Integrating Virtual Screening and In Vitro Validation.

Authors:  Baoyue Zhang; Jun Zhao; Zhe Wang; Pengfei Guo; Ailin Liu; Guanhua Du
Journal:  Front Pharmacol       Date:  2021-07-16       Impact factor: 5.810

8.  Chuanxiong Formulae for Migraine: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials.

Authors:  Chun-Shuo Shan; Qing-Qing Xu; Yi-Hua Shi; Yong Wang; Zhang-Xin He; Guo-Qing Zheng
Journal:  Front Pharmacol       Date:  2018-06-27       Impact factor: 5.810

Review 9.  Panax ginseng as an adjuvant treatment for Alzheimer's disease.

Authors:  Hyeon-Joong Kim; Seok-Won Jung; Seog-Young Kim; Ik-Hyun Cho; Hyoung-Chun Kim; Hyewhon Rhim; Manho Kim; Seung-Yeol Nah
Journal:  J Ginseng Res       Date:  2018-01-12       Impact factor: 6.060

10.  Acid-base fractions separated from Streblus asper leaf ethanolic extract exhibited antibacterial, antioxidant, anti-acetylcholinesterase, and neuroprotective activities.

Authors:  Anchalee Prasansuklab; Atsadang Theerasri; Matthew Payne; Alison T Ung; Tewin Tencomnao
Journal:  BMC Complement Altern Med       Date:  2018-07-24       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.